A large Australian study found important differences between younger and older adults with advanced bowel cancer. Researchers analyzed 1,691 patients whose cancer had spread only to the liver. Patients diagnosed at 50 or younger were more likely to be women, have left-sided tumors and carry certain genetic mutations. They also had better overall survival than older patients after the cancer spread to the liver.
The study was led by Flinders University and Flinders Medical Centre and published in the Medical Journal of Australia.
ALSO READ: Madonna eyes Angelina Jolie’s $29.85 million Los Feliz mansion after virtual tour
Why the liver matters in advanced bowel cancer
The liver is the most common place for bowel cancer to spread. Researchers found that patients who had liver surgery followed by drug treatment generally had better outcomes. However, the study was based on routine clinical data, not a clinical trial, so it cannot prove that surgery itself caused longer survival.
BRAF and KRAS mutations linked to poorer outcomes
The researchers found that BRAF and KRAS mutations were associated with poorer outcomes in both younger and older patients.
The findings highlight the potential importance of genetic testing when doctors assess advanced bowel cancer.
Professor Savio (George) Barreto of Flinders Medical Centre said: "We still have much to learn about why these cancers develop and how they differ from those diagnosed in older people. Our study helps build a clearer picture of the disease and suggests that younger patients may have distinct tumor characteristics that should be considered when treatment decisions are being made."
ALSO READ: Robert Kiyosaki says he’s $1.2 billion in debt
Age is not the only factor
The researchers say treatment decisions should consider more than a patient's age, including tumor genetics, cancer spread and overall health. "Our findings reinforce the need to look beyond a patient's age when planning treatment because every cancer is unique," says Professor Barreto.
"The more we understand about the biology of a tumor, the better equipped we are to tailor treatment and identify the options most likely to benefit each patient."
